

CIED lead management considerations for the non-extracting device manager

References

1. Kusumoto et al. 2017 HRS Expert Consensus statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction. *Heart Rhythm*, 2017.
2. Pokorney et al. Outcomes Associated with Extraction versus Capping and Abandoning Pacing and Defibrillator Leads *Circulation* 2017 Oct 10;136(15):1387-1395. doi: 10.1161/CIRCULATIONAHA.117.027636. Epub 2017 Aug 22.
3. Hussein et al. Microbiology of Cardiac Implantable Electronic Device Infections. *J Am Coll Cardiol EP* 2016;2:498–505 *Circ Arrhythm Electrophysiol*.
4. Sohal, M. et al. (2014). Laser lead extraction to facilitate cardiac implantable electronic device upgrade and revision in the presence of central venous obstruction. *Europace*, 16(1), 81-87.
5. Oginozawa Y, Abe H, Nakashima Y. The incidence and risk factors for venous obstruction after implantation of transvenous pacing leads. *Pacing Clin Electrophysiol* 2002;25:1605–1611.
6. Kutarski, A., Pietura, R., Młynarczyk, K., Małecka, B., & Główniak, A. (2012). Pacemaker lead extraction and recapture of venous access: technical problems arising from extensive venous obstruction. *Cardiology journal*, 19(5), 513-517.
7. de Cock CC, et al. Long-term outcome of patients with multiple (> or = 3) noninfected leads: a clinical and echocardiographic study. *PACE*, Vol 23, No 4, 2000, 423-6
8. Kalin R, Stanton MS. Current clinical issues for MRI scanning of pacemaker and defibrillator patients. *PACE*. April 2005;28(4):326-328.
9. Voight, Andrew, et al. Rising Rates of Cardiac Rhythm Management Device Infections in the United States: 1996 through 2003. *JACC* Vol. 48, No. 3. 2006:590-1.
10. Voight, Andrew, et al. Continued Rise in Rates of Cardiovascular Implantable Electronic Device Infections in the United States: Temporal Trends and Causative Insights. *PACE* Vol. 33. No. 4, 2010:414-9.
11. Del Rio A, Anguera I, Miro JM, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: The impact of electrode lead extraction on outcome. *Chest* 2003; 124:1451.
12. Chua JD, et al. (2000). Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. *Annals of Internal Medicine*, 133(8): 604-608.
13. Klug D, et al. (2004). Local symptoms at the site of pacemaker implantation indicate latent systemic infection. *Heart*, 90(8); 882-886.
14. Margey R, et al. Contemporary management of and outcomes from cardiac device related infections. *Eurospace* (2010) 12(1):64-70, first published online November 11,2009 doi:10.1093/eurospace/eup362.
15. Wazni O et al. Lead Extraction in the Contemporary Setting: The LExCon Study: A multicenter Observational Retrospective Study of Consecutive Laser Lead Extractions, *J Am Coll Cardiol*, 55:579-586.
16. Le KY, Sohail MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electrophysiologic device infections. *Heart Rhythm* 2011; 8:1678-85.
17. Wilkoff BL, et al. (2009). Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management. *Heart Rhythm*, 6, 1085-1104.
18. Baddour LM, et al. (2010) Update on cardiovascular implantable electronic device infections and their management: A scientific statement from the American Heart Association. *Circulation*, 121, 458-477. Occult gram-positive bacteremia.
19. Kern M. SCAI Interventional Cardiology Board Review Book. Lippincott Williams & Wilkins 2006; p.165.
20. Barbanti M, Petronio AS, Capodanno D, et al. Impact of balloon post-dilation on clinical outcomes after transcatheter aortic valve replacement with the self-expanding CoreValve prosthesis. *JACC Cardiovasc Interv* 2014;7:1014–21. 10.1016/j.jcin.2014.03.009
21. Doshi R, Decter DH, Meraj P. Incidence of arrhythmias and impact of permanent pacemaker implantation in hospitalizations with transcatheter aortic valve replacement. *Clin Cardiol*. 2018;41:640–645.

22. Culler, SD, Cohen, DJ, Brown, PP. Trends in aortic valve replacement procedures between 2009 and 2015: has transcatheter aortic valve replacement made a difference? *Ann Thorac Surg* 2018; 105: 1137–1143.
23. Poole, J. et. al., Complication Rates Associated with Pacemaker and ICD Generator Replacements when Combined with Planned Lead Addition or Revision, American Heart Association, November 15, 2009.
24. Elayi CS, Darrat Y, Suffredini JM, et al. Sex differences in complications of catheter ablation for atrial fibrillation: Results on 85,977 patients. *J Intervent Cardiac Electrophysiol*. 2018:1-7.
25. Khan MN, et al. Pulmonary-vein isolation for atrial fibrillation in patients with HF. *N Engl J Med* 2008;359(17):1778–1785.
26. Jones DG, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in HF. *J Am Coll Cardiol* 2013; 61(18):1894–1903.
27. Hummel J, et al. Phased RF ablation in persistent atrial fibrillation. *Heart Rhythm* 2014;11(2):202–209.
28. Brignole, M. et. al., Defibrillation testing at the time of implantation of cardioverter defibrillator in the clinical practice: a nation-wide survey, *Europace* 2007 Vol. 9 No. 7: 540-543.
29. Ryan Azarrafiy, BA; Darren C. Tsang, BS; Bruce L. Wilkoff, MD, FHRS; Roger G. Carrillo, MD, MBA, FHRS. The Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction: A Multi-Year Analysis and An Update to Best Practice Protocol. *Circulation: Arrhythmia and Electrophysiology*. August 2019.
30. Byrd Charles, et al. Clinical Study of the Laser Sheath for Lead Extraction: The Total Experience in the United States. *Journal of Pacing and Electrophysiology*. Vol 25, No. 5, May2002.